Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
Kang Cheng, Chenfu Liu, Guo‐Wu Rao
Abstract
Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of drug development and chemical synthesis.
Topics & Concepts
AngiogenesisVascular endothelial growth factorKinase insert domain receptorCancer researchReceptor tyrosine kinasePharmacologyTyrosine kinaseReceptorVascular endothelial growth factor AGrowth factor receptor inhibitorVascular endothelial growth factor CVEGF receptorsChemistryMedicineGrowth factorBiochemistryAngiogenesis and VEGF in CancerCancer Mechanisms and TherapyGastric Cancer Management and Outcomes